• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.46
▲ +0.01 (2.22%)

This chart shows the closing price for LCI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lannett Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LCI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Lannett in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.46.

This chart shows the closing price for LCI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Lannett. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/31/2021Roth CapitalLower TargetNeutral$7.00 ➝ $6.00High
6/10/2021Roth CapitalLower TargetNeutral$7.50 ➝ $7.00High
11/3/2020Raymond JamesReiterated RatingHoldHigh
8/27/2020Roth CapitalBoost TargetNeutral$9.00 ➝ $11.00Medium
8/27/2020BMO Capital MarketsReiterated RatingHold$6.00High
8/27/2020Raymond JamesReiterated RatingHoldHigh
8/17/2020Raymond JamesReiterated RatingHoldHigh
9/18/2019SunTrust BanksBoost TargetHold$10.00 ➝ $14.00Medium
8/29/2019SunTrust BanksBoost TargetHold$10.00High
8/28/2019Roth CapitalReiterated RatingNeutralHigh
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$9.00Medium
12/13/2018Raymond JamesReiterated RatingHoldHigh
8/20/2018BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$19.00 ➝ $8.00High
8/20/2018Raymond JamesDowngradeOutperform ➝ Market Perform$43.00High
8/20/2018Craig HallumDowngradeBuy ➝ HoldLow
8/20/2018Roth CapitalDowngradeBuy ➝ Neutral$23.00 ➝ $27.50High
5/9/2018OppenheimerReiterated RatingHoldLow
3/22/2018OppenheimerReiterated RatingHoldHigh
2/8/2018BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$22.00 ➝ $21.00Low
2/7/2018Roth CapitalSet TargetBuy$25.00Low
2/7/2018OppenheimerReiterated RatingHoldLow
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$21.00Medium
12/11/2017OppenheimerReiterated RatingHoldLow
11/13/2017BMO Capital MarketsBoost TargetMarket Perform$20.00 ➝ $22.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/6/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/5/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
9/4/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/4/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Lannett logo
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Read More

Today's Range

Now: $0.46
Low: $0.45
High: $0.46

50 Day Range

MA: $0.53
Low: $0.45
High: $0.63

52 Week Range

Now: $0.46
Low: $0.43
High: $2.97

Volume

97,116 shs

Average Volume

314,913 shs

Market Capitalization

$19.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Lannett?

The following Wall Street analysts have issued research reports on Lannett in the last twelve months: StockNews.com.
View the latest analyst ratings for LCI.

What is the current price target for Lannett?

0 Wall Street analysts have set twelve-month price targets for Lannett in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Lannett in the next year.
View the latest price targets for LCI.

What is the current consensus analyst rating for Lannett?

Lannett currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LCI.

What other companies compete with Lannett?

How do I contact Lannett's investor relations team?

Lannett's physical mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company's listed phone number is (215) 333-9000. The official website for Lannett is www.lannett.com. Learn More about contacing Lannett investor relations.